Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 126.50 123.00 130.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -0.6 -4.7 - 20

Aortech Share Discussion Threads

Showing 8751 to 8774 of 8900 messages
Chat Pages: 356  355  354  353  352  351  350  349  348  347  346  345  Older
DateSubjectAuthorDiscuss
27/5/2020
10:02
Easy to sell in volume. Impossible to buy volume
amt
27/5/2020
09:55
We look forward to the wider population of investors receiving an eyeful of Aortech’s assets.
bones
27/5/2020
09:30
t0pgrader, its distributed to Shore Cap clients, institutions etc, it is however on some of the research accumulator sites. If the company is preparing to give Shore Cap a full skirt lift, I suspect they will be doing the same with Equity DEvelopment and Andy Smith.
landy90
27/5/2020
09:11
landy90 - is Shore Cap research generally available? Thanks
t0pgrader
27/5/2020
08:49
I agree and I'm very much looking forward to it having held these for several years
herschel k
27/5/2020
08:29
Note the new line from Shore Capital: we now also intend to set out a timeline of the potential significant milestones that will be achieved over the coming 12-18 months. There is a major push coming here.
landy90
27/5/2020
08:26
Comments from Shore Capital this morning: Trading Comments - AOR AORTECH INTERNATIONAL+ (AOR, House Stock, 105p) US patent granted/animal trials on grafts to begin AorTech has this morning announced that the United States Patent and Trademark Office has notified it that will issue a new patent in relation to its ElastEon technology. The invention relates to the process of manufacture of biomaterials for use in implantable medical devices including polymeric heart valves. We are encouraged by this development as AorTech looks to extend the life and range of its intellectual property protection. We also view positively the news that AorTech expects to commence animal testing on the ElastEon sealed graft in the coming weeks, which is at an earlier stage than we had anticipated at the time of the trading update on 12 May 2020. Our comment on the recent trading update flagged that we intend to publish a more detailed note on the likely implications of the RUA acquisition with updated forecasts at the time of the final results scheduled for July 2020. At that stage, we now also intend to set out a timeline of the potential significant milestones that will be achieved over the coming 12-18 months. HOUSE STOCK
landy90
27/5/2020
08:10
Perhaps the market is finally waking up to the fact that Aortech is doing much more than just licensing out some old IP!
bones
27/5/2020
08:09
Still some way to the 676p valuation
amt
27/5/2020
08:01
Very very significant development IMO.
langland
27/5/2020
08:01
It's all coming together now.
someuwin
27/5/2020
07:07
More highly significant news today. All steam ahead. I wonder if shares will go through the roof like many Biotec shares have done recently for different reasons but also more focus on this sector now.
amt
27/5/2020
07:06
27 May 2020 AorTech International plc ("AorTech" or the "Company") New Patent AorTech International plc (AIM: AOR.L), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon (TM) ), is pleased to announce that the United States Patent and Trademark Office has notified AorTech that its Application Number 15/995,050 will issue as Patent Number 10,676,560 entitled "BIOSTABLE POLYURETHANES" on 9th June 2020. The invention relates to a biostable polyurethane or polyurea comprising: (a) a soft segment comprising a polysiloxane of the general formula disclosed in the Patent; and (b) greater than 0 and less than 40 wt % of a hard segment which is a reaction product of a diisocyanate and a linear difunctional chain extender, processes for their preparation and their use in the manufacture of biomaterials, implantable medical devices and polymeric heart valves. Bill Brown, Chairman of AorTech, said : "We are delighted that at the same time as major steps are being made in the development of our ElastEon (TM) enabled medical devices, our Intellectual Property portfolio relating to the ElastEon(TM) family of world class biostable polymers has been expanded further by the grant of this latest US patent. We currently anticipate reaching the significant milestone of commencing animal testing on the ElastEon (TM) sealed graft in the coming weeks."
someuwin
26/5/2020
18:48
I get the impression that whilst covid issues are disrupting production of products for customers , it is full steam ahead on developing its own devices and IP surrounding them and would not be surprised to see a stream of news into the summer. As mentioned by others the positive tone from the company recently from a historically conservative BOD is telling.
landy90
26/5/2020
18:33
Two more late reported 25k trades reported from Friday morning which makes four of that size in recent days. Silent accumulation by serious players?
bones
26/5/2020
18:29
Regarding the resumption of heart surgery in the US, the linked article below gives an indication of the headaches faced by the hospitals, namely always needing to allow for Covid waves but also to “entice” those with serious health problems to actually attend hospital!! However, this quote sounds like it might be what RUA Medical needs to hear: “... Similarly, at WVU Medicine, a committee consisting of representatives from every surgical department meets daily to review every case. Those with significant heart and valve and blood vessel diseases have been prioritized in Phase 1, as have some cancer patients, Hoffmann says. “Every physician feels like their case is important, but we have to look at the big picture,” he says. “It’s a little bit of numbers but then also some decision-making among physicians and administrative staff ...” https://www.aamc.org/news-insights/hospitals-cautiously-resume-some-surgeries
bones
26/5/2020
13:24
cfb2, lol!
bones
26/5/2020
13:09
Cheers landy Edwards Lifestyles Corp NYSE:EW. Market Cap 45bn
someuwin
26/5/2020
12:56
Germany are paying 35k Euro and its about $45k in the US.
landy90
26/5/2020
12:43
£20k is the device not the op... The patient being handed the bill would be when they stress test the valve.
cfb2
26/5/2020
12:18
No online quote for even small amounts, got to let this go soon.
nimbo10
26/5/2020
12:12
Blimey...that's quite an eye-opener.
langland
26/5/2020
12:05
£20k is the device not the op, that is what has driven the share price of Edwards over the last 10 years TAVI devices are circa 10X surgical valves.
landy90
26/5/2020
11:50
The Takeover / merger with RUA Medical will bring a huge amount of new opportunities. The experience and no doubt long list of clients will be hugely advantageous. I suspect there's a lot more going on in the background here than we are aware of - yet! "Here are a range of medical device products and systems that the RUA Medical team have worked on: * Straight, tapered and bifurcated vascular and endovascular tubular implants * Male and Female Urinary Incontinence systems * Mechanised sewing of wire scaffolds onto circular, tapered and bifurcated endovascular implant fabrics. * Woven tapered bifurcated vascular and endovascular delivery systems * Spinal lumber stabilisation implants * AAA and thoracic stent grafts * Synthetic spinal disc replacement implants * Pelvic organ prolapse mesh systems * 3D tissue growth support scaffolds (permanent & reabsorbable) * Synthetic ligaments * PTFE mesh and implantable fabrics * Hernia mesh systems * Reabsorbable and composite mesh systems * Cuff fabrics * Stent covering systems * Knitted pessary system * Medical Coatings * Silver Ion release urology catheters. * Reabsorbable and composite mesh systems * Antimicrobial solutions * Alginate wound care systems * Personal care systems * Catheter securement system * Braided Suture Systems * Blood monitoring system * Heart Surgery retractor * Knitted and woven dental floss systems * Single use instruments"
someuwin
Chat Pages: 356  355  354  353  352  351  350  349  348  347  346  345  Older
ADVFN Advertorial
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210727 03:01:43